Latest antibody News

Miles Doing What Matters: Free RSV immunisation success for Queensland newborns
JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)
Telix completes proof-of-concept study of TLX592 in prostate cancer
Immutep appoints research institute to conduct first-in-human study of IMP761
Free RSV immunisation program for Queensland infants and young children
Pradeepa Pushparaj is awarded Sven Gard´s scholarship 2024
2024 RSV Infant Immunisation Program
Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
Full Year and Q4 2023 results
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Why you should feed both cold and fever
World-first breakthrough in malaria treatment
La Trobe University and AdAlta collaboration delivers world-first breakthrough in malaria treatment
FDA grants fast-track designation for EnGeneIC’s pancreatic cancer candidate
Statement on the antigen composition of COVID-19 vaccines
Being overweight hampers immune response to SARS-CoV-2
AstraZeneca advances scientific leadership in haematology at ASH 2023
Social network of proteins
Telix says first patient dosed in ProstACT study of prostate cancer candidate
9M and Q3 2023 results
Imugene announces phase 1 clinical trial opens with onCARlytics CD19 virus technology
Arovella Therapeutics licences monoclonal antibody for cell therapy development
New treatment offers hope for advanced liver cancer
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01…
Imugene secures new patent in Japan for PD1-Vaxx clinical drug candidate
Enhertu demonstrated strong and durable tumour responses in previously treated HER2-mutant advanced lung cancer in DESTINY-Lung02 Phase II trial
Advanced Technology Reveals Intricate Details of Zinc Transportation in Cells
Does picking your nose really increase your risk of COVID?
Enhertu demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial
Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial
Mater midwife’s life-saving gift to thousands of mothers
Datopotamab deruxtecan combinations showed encouraging tumour responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
Update on brazikumab development programme
Making Vaccines Longer Lasting
Radiopharm Theranostics and GenesisCare partner on development of radiopharmaceutical
Novel Regulatory Mechanism of Blood Clotting Discovered
Patrys’ says preclinical data supports synthetic lethality mechanism
Enhertu showed clinically meaningful and durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial
CSL reports positive results from pivotal late-stage trial of first-in-class garadacimab
TGA provisionally approves Moderna’s new bivalent Covid vaccine
TGA grants provisional approval to Moderna’s COVID-19 bivalent (SPIKEVAX Bivalent Original/Omicron BA.4-5) booster dose vaccine
TGA grants provisional approval to Pfizer’s COVID-19 bivalent (COMIRNATY Original/Omicron BA.4-5 COVID-19 vaccine) booster dose vaccine
WHO updates COVID-19 guidelines on masks, treatments and patient care
Exploring air we breathe
Datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated HR-positive
Anatomical barriers shield brain from SARS-CoV-2 invasion at vulnerable interfaces
Enhertu achieved statistically significant overall survival, reducing risk of death by 36% vs. trastuzumab emtansine